📈 Fed's first cut since 2020: Time to buy the dip? See Tech-focused stock picksUnlock AI Picks

Entero Therapeutics Inc (ENTO)

NASDAQ
Currency in USD
Disclaimer
0.3661
+0.0171(+4.90%)
Closed
ENTO Scorecard
Full Analysis
Trading at a low Price / Book multiple
Fair Value
Day's Range
0.31100.3899
52 wk Range
0.185014.5100
Prev. Close
0.349
Open
0.372
Day's Range
0.311-0.3899
52 wk Range
0.185-14.51
Volume
114,548
Average Vol. (3m)
595,767
1-Year Change
-96.03%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
ENTO Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
36.0000
Upside
+9,733.3789%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week
Show more

Entero Therapeutics Inc Company Profile

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.

Compare ENTO to Peers and Sector

Metrics to compare
ENTO
Peers
Sector
Relationship
P/E Ratio
−0.2x−2.9x−0.6x
PEG Ratio
0.00−0.030.00
Price / Book
0.1x2.4x2.6x
Price / LTM Sales
-12.3x3.1x
Upside (Analyst Target)
10,215.2%206.8%55.8%
Fair Value Upside
Unlock0.1%7.3%Unlock

People Also Watch

3.150
VTGN
-4.26%
0.680
HEPA
-8.11%
0.279
MLGO
+20.52%
0.6150
WTO
-6.82%

FAQ

What Is the Entero Therapeutics (ENTO) Stock Price Today?

The Entero Therapeutics stock price today is 0.3661

What Stock Exchange Does Entero Therapeutics Trade On?

Entero Therapeutics is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Entero Therapeutics?

The stock symbol for Entero Therapeutics is "ENTO."

What Is the Entero Therapeutics Market Cap?

As of today, Entero Therapeutics market cap is 1.14M.

What is Entero Therapeutics Earnings Per Share?

The Entero Therapeutics EPS is -8.61.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.